Omega-3 triglycerides

Brand Abbott

In stock 1330 Items

Available since: 2019-09-19

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Omacor - lipid-lowering drug. Contains polyunsaturated essential fatty acids of the omega-3 class - eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - are irreplaceable (essential) fatty acids (NEFA).

Omacor reduces triglycerides by reducing the concentration of very low density lipoproteins (VLDL), in addition, it actively affects hemostasis, reducing the synthesis of thromboxane A2 and slightly increasing the clotting time of the blood.

Delays the synthesis of triglycerides in the liver (by inhibiting the esterification of EPA and DHA).

An increase in peroxisome beta-oxidation of fatty acids (a decrease in the amount of free fatty acids available for the synthesis of triglycerides) contributes to a decrease in triglyceride levels.

The increase in high-density lipoprotein (HDL) is very small and not constant. It is significantly less than after taking fibrates.

The results of observations (within 3.5 years) of patients taking Omacor at a dose of 1 g / day showed a significant reduction in the combined index, including all-cause mortality, as well as non-fatal myocardial infarction and stroke.

Indications

secondary prevention of myocardial infarction (in combination with other standard treatment methods: statins, antiaggregatory agents, beta-blockers, ACE inhibitors);
hypertriglyceridemia: endogenous hypertriglyceridemia - as a supplement to the diet with its lack of efficacy: type IV (as monotherapy), types IIb / III (in combination with statins - when the triglyceride concentration remains high).

Composition

1 capsule contains:

Active substances: Omega-3 ethyl esters 1 g, incl. eicosapentaenoic acid ethyl ester (EPA) 46%, docosahexaenoic acid ethyl ester (DHA) 38%, α-tocopherol.

No customer reviews for the moment.

Write your review

Dosage and Administration

The drug is taken orally, during the meal.

For the secondary prevention of myocardial infarction, it is recommended to take 1 capsule per day.

When treating hypertriglyceridemia, the initial dose of Omacor is 2 capsules per day. In the absence of a therapeutic effect, it is possible to increase the dose to 4 capsules per day.

The duration of treatment is set individually.

Patients with impaired renal function dose adjustment is not required.

Adverse reactions

Infectious processes: infrequently - gastroenteritis.

On the part of the immune system: infrequently - increased sensitivity.

Metabolism and nutrition disorders: rarely - hyperglycemia.

From the nervous system: infrequently - dizziness, dysgeusia (taste perversion); rarely - headache.

Vascular disorders: very rarely - lowering blood pressure.

On the part of the respiratory, chest and mediastinal organs: very rarely - dry nose.

From the digestive tract: often - dyspepsia, nausea; infrequently - abdominal pain, gastrointestinal disorders, gastritis, pain in the upper abdomen; very rarely - bleeding from the lower GI tract.

Liver: rarely - liver dysfunction.

On the part of the skin and subcutaneous fat: rarely acne, itchy rashes; very rarely - hives.

In the course of research: there was very rarely an increase in the number of blood leukocytes, blood lactate dehydrogenase. Patients with hypertriglyceridemia reported a moderate increase in transaminases (AST, ALT).

Reports of sporadic side effects.

Metabolism and nutrition disorders: increased insulin requirements (the need to increase the standard dose).

Liver disorders: increased liver enzymes.

Violations of the skin and subcutaneous tissues: rosacea, rash, redness / erythema, urticaria in the chest, neck and shoulders.

Contraindications

The drug should be prescribed with caution in case of marked impaired liver function, while being used with fibrates, with oral anticoagulants, with severe injuries, surgical operations (due to the risk of increased bleeding time), elderly patients (over 70 years of age), and children and adolescents under the age of 18 years (efficacy and safety have not been established).

Drug interactions

With the simultaneous use of Omacor with oral anticoagulants, there is a risk of increased bleeding time.

Appointment of Omacor along with warfarin does not lead to any hemorrhagic complications. However, when combined with Omakor and warfarin, or if Omakor stops treatment, it is necessary to control prothrombin time.

Pregnancy and Lactation

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Special instructions

In connection with a moderate increase in bleeding time (when taking a high dose - 4 caps.), Monitoring of patients undergoing anticoagulant therapy is required, and, if necessary, a corresponding dose adjustment of the anticoagulant. Conducting this therapy does not preclude the need for routine control in the treatment of such patients. The increase in bleeding time in patients with an increased risk of hemorrhage (as a result of severe injury, surgery, etc.) should be taken into account. Experience in the study of secondary endogenous hypertriglyceridemia (especially uncontrollable diabetes mellitus) is very limited. There is no clinical experience regarding the treatment of hypertriglyceridemia in combination with fibrates. When you receive Omacor, a moderate increase in the activity of liver transaminases is possible. In patients with impaired liver function (especially when taking a high dose - 4 caps.) Requires regular monitoring of liver function (AST and ALT). Information about the use of the drug Omacor in children, elderly patients older than 70 years or in patients with impaired liver function is not available.In patients with impaired renal function, dose adjustment is not required.